Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences’ Application for WAKIX® (Pitolisant) in Pediatric Narcolepsy